Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy

  • Authors:
    • Ju Han Song
    • Kyung-Min Cho
    • Hyeoung-Joon Kim
    • Yeo-Kyeoung Kim
    • Nan Young Kim
    • Hee-Je Kim
    • Tae-Hyang Lee
    • Seung Yong Hwang
    • Tae Sung Kim
  • View Affiliations

  • Published online on: May 7, 2015     https://doi.org/10.3892/or.2015.3959
  • Pages: 488-494
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the t(8;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)-positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95% confidence interval (CI), 0.025-0.557; P=0.008] and overall survival (HR, 0.062; 95% CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients.
View Figures
View References

Related Articles

Journal Cover

July-2015
Volume 34 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Song JH, Cho K, Kim H, Kim Y, Kim NY, Kim H, Lee T, Hwang SY and Kim TS: Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. Oncol Rep 34: 488-494, 2015
APA
Song, J.H., Cho, K., Kim, H., Kim, Y., Kim, N.Y., Kim, H. ... Kim, T.S. (2015). Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy. Oncology Reports, 34, 488-494. https://doi.org/10.3892/or.2015.3959
MLA
Song, J. H., Cho, K., Kim, H., Kim, Y., Kim, N. Y., Kim, H., Lee, T., Hwang, S. Y., Kim, T. S."Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy". Oncology Reports 34.1 (2015): 488-494.
Chicago
Song, J. H., Cho, K., Kim, H., Kim, Y., Kim, N. Y., Kim, H., Lee, T., Hwang, S. Y., Kim, T. S."Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy". Oncology Reports 34, no. 1 (2015): 488-494. https://doi.org/10.3892/or.2015.3959